Table 1.

u-PAR expression in human ovarian cancer

Total number(%)(N=162)u-PAR expression score
Low (<120)High(≥120)
(N=81)(N=82)
OvCaStage
I19 (11.7)910
II8 (4.9)44
III93 (57.5)4548
IV42 (25.9)2220
Histology
Serous-papillary115 (71.0)5263
Endometrioid22 (13.6)139
Clear cell15 (9.3)96
Mucinous10 (6.2)64
Grading
G113 (8.0)85
G239 (24.1)1623
G3110 (67.9)5654
Residual tumor
≤1 cm95 (58.6)4946
>166 (40.7)3135
unknown1 (0.6)10
Chemotheraphy type
Neo-adjuvant19 (11.7)811
Primary133 (82.1)6865
None10 (6.2)46
Chemotheraphy
Taxane/Platinum140 (86.4)7070
Platinum6 (3.8)51
Other6 (3.7)15
None10 (6.2)46

NOTE: Clinical data of patients with stage I–IV ovarian cancer (OvCa; n = 162). Immunoscoring was performed with the Automated Cellular Imaging System, and the u-PAR expression scores are reported as high if greater than or equal to the median score (120) or low if less than median score.